8:30 am Morning Networking Coffee
8:55 am Chair’s Opening Remarks
Discovering Better Biomarkers for Clinical Monitoring & Exploring New Therapeutic Avenues to Treat Patients in Need
9:00 am Harnessing the Endogenous Melanocortin System to Resolve IBD – A New Paradigm to Treat Inflammatory Diseases
Synopsis
- Biasing tissue and immune cells towards resolving inflammation
- Unprecedented safety by employing the natural mode of resolution removes efficacy/ toxicity balance considerations
- Exploring the need for and type of patient stratification biomarkers
9:30 am Using Biomarkers to Change our Approach to Early Clinical Development
Synopsis
- Proof of concept studies (POC) today are time consuming, costly and deliver undifferentiated therapeutic options for patients mainly because current clinical endpoints lack dynamic range and carry imprecisions
- Defining complementary molecularly based clinical endpoints with high dynamic ranges and very low intra- and inter-assessor variability would beneficially impact the duration of POC studies
- Defining complementary molecular-based clinical endpoints would also allow a thorough comparison of existing and upcoming therapeutics in a disease areaÂ
10:00 am Morning Networking Break
Enhancing Safety & Efficacy to Accelerate Patient Access to Personalized Drugs
11:00 am Achieving the Selectivity Required for the Elusive Trifecta of Safety, Efficacy, & Convenience in IBD Drug Development
Synopsis
- Driving high selectivity of integrin-targeted medicines with Morphic’s MInT Platform
- Leveraging understanding of integrin structure and function to develop novel molecules designed to achieve the potency, high selectivity, and pharmaceutical properties required for oral administration
- Employing innovative end points to accelerate decision making for POC studies in IBD
11:30 am Harnessing Biomarker Signatures for Phenotypic Stratification in IBD: Leveraging a Precision Medicine approach to maximize the mechanistic potential of ESN-X
Synopsis
- Deep molecular phenotyping addresses the complexities of the underlying biology in IBD.
- Multi-omics and machine learning enable identification of patients most likely to benefit from specific drugs.
11:40 am Roundtable Discussion: Companion Diagnostics, Data Handling, & Effective Drug Development – The Future Steps
Synopsis
- Handling real-world data to evaluate the long-term efficacy and safety of IBD treatments.
- Leveraging companion diagnostics to facilitate personalized treatment approaches for IBD
- How can companion diagnostics predict the efficacy of combination therapies?
- What is the most effective source of data for achieving accurate and reliable companion diagnostics?
- What steps should we be taking to collect, store, and handle data to inform better decisions regarding the right drug, to the right patient, at the right time?
12:40 pm Lunch and Networking Break
Delving into Novel Approaches to Deliver Best-In-Class IBD Drugs to Patients in Need
1:40 pm Panel Discussion: Exploring the Fusion of Novel Approaches to Comprehensively Tackle IBD
Synopsis
- Can research into the microbiome work in unison with other new approaches to provide a deeper understanding of IBD?
- Which therapeutic avenues remain underexplored and should be focused on?
- How will developments in cutting-edge drug delivery technologies enhance treatment precision?
- The holistic understanding – combining our knowledge, old and new, to pave the steps for future research into IBD
2:40 pm Unconventional Players in IBD Pathogenesis & Precision Therapies
Synopsis
- An in-depth exploration for the capacity of emerging approaches regarding non-immune cells to revolutionize our understanding of IBD
- Exploring the capacity for precision medicine strategies target these unconventional players to open new avenues for IBD treatment innovation
3:10 pm Biological Differences on Population and Individual Levels Provide Intriguing Data for Precision Medicine in IBD
Synopsis
- The discovery and the differential downstream signal of a protective allele in MRGPRX2 highlighted the importance of investigating biological differences on population level
- Individual variations in certain cell types and biological processes can be highly valuable for drug response prediction and for further forwarding the boundary of basic science